|
1. Warnakulasuria S. Living
with oral cancer; epidemiology with particular
reference to prevalence and life style changes that
influence survival. Oral Oncol.
2010;46:407-10.
https://doi.org/10.1016/j.oraloncology.2010.02.015
PMid:20403722
|
|
|
|
2. Abbey LM,
Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA,
et al. Inrtraexaminer and interexaminer reliability in
the diagnosis of oral epithelial dysplasia. Oral Surg
Oral Med Oral Pathol Oral Radiol. 1995; 80;188-91.
https://doi.org/10.1016/S1079-2104(05)80201-X
PMid:7552884
|
|
|
|
|
3. Pitiyage G, Tilakaratne WM,
Tavassoli M, Warnakulasuriya S. Molecular markers in
oral epithelial dysplasia; review. J Oral Pathol Med.
2009;38:737-52.
https://doi.org/10.1111/j.1600-0714.2009.00804.x
PMid:19903246
|
|
|
|
|
4. Reibel J. Prognosis of oral
premalignant lesions; significance of clinical, histopathological
and molecular biological characteristics. Crit
Rev Oral Biol Med. 2008;14:47-62.
https://doi.org/10.1177/154411130301400105
PMid:12764019
|
|
|
|
|
5. Schepman S, Gorosky M,
Lozada F. Oral leukoplakia and malignant
transformation; a follow up study of 257 patients. Cancer.
1984;53:563-8.
https://doi.org/10.1002/1097-0142(19840201)53:3<563::AID-CNCR2820530332>3.0.CO;2-F
PMid:6537892
|
|
|
|
|
6. Silverman S, Bhargava K,
Smith LW, Malaowalla AM. Malignant transformation and
natural history of oral leukoplakia in 57,518
industrial workers of Gujarat, India. Cancer.
1976;38:1790-5.
https://doi.org/10.1002/1097-0142(197610)38:4<1790::AID-CNCR2820380456>3.0.CO;2-I
PMid:1033027
|
|
|
|
|
7. Holmstrup P, Vedtofte P,
Reibel J, Stoltze K. Long-term treatment outcome of
oral premalignant lesions. Oral
Oncol. 2006;42:461-74.
https://doi.org/10.1016/j.oraloncology.2005.08.011
PMid:16316774
|
|
|
|
|
8. Inoue H,
Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, et
al. Podoplanin expression during dysplasia–carcinoma
sequence in the oral cavity. Tumor
Biol. 2012;33:183-94.
https://doi.org/10.1007/s13277-011-0261-7
PMid:22081310
|
|
|
|
|
9. Warnakulasuriya S, Reibel
J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia
classification systems: predictive value, utility, weaknesses
and scope for improvement. J Oral Pathol Med. 2008;27:127-33.
https://doi.org/10.1111/j.1600-0714.2007.00584.x
PMid:18251935
|
|
|
|
|
10. Wicki A, Christofori G.
The potential role of podoplanin in tumour invasion. Br
J Cancer. 2007;96:1-5.
https://doi.org/10.1038/sj.bjc.6603518
PMid:17179989 PMCid:PMC2360213
|
|
|
|
|
11. Breiteneder-Geleff S,
Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R et
al. Podoplanin, novel 43 kDa membrane protein of
glomerular epithelial cells, is down-regulated in
puromycin nephrosis. Am J
Pathol. 1997;151:1141-52.
PMid:9327748 PMCid:PMC1858024
|
|
|
|
|
12. Raica M, Cimpean AM,
Ribatti D. The Role of Podoplanin in Tumor Progression
and Metastasis. Anticancer Res.
2008;28:2997-3006.
PMid:19031946
|
|
|
|
|
13. Franchi A, Gallo O, Massi
D, Baroni G, Santucci M. Tumor lymphangiogenesis in
head and neck squamous cell carcinoma- a morphometric
study with clinical correlations. Cancer
2004;101:973-8.
https://doi.org/10.1002/cncr.20454
PMid:15329906
|
|
|
|
|
14. Huber GF, Fritzsche FR,
Zullig L, Storz M, Graf N, Haerle SK et al. Podoplanin
expression correlates with sentinel lymph node
metastasis in early squamous cell carcinomas of the
oral cavity and oropharynx. Int
J Cancer. 2011;129:1404-9.
https://doi.org/10.1002/ijc.25795
PMid:21105028
|
|
|
|
|
15. Martin –Villair E, Scholl
FG, Gamallo C et al. Characterization of human PA2.26
antigen (T1 alpha 2, podoplanin), a small membrane
mucin induced in oral squamous cell carcinomas. Int
J Cancer. 2005;11:899-910.
https://doi.org/10.1002/ijc.20656
PMid:15515019
|
|
|
|
|
16. Kawaguchi H, El-Naggar AK,
Papadimitrakopoulou V, Ren H, Fan YH, Feng L.
Podoplanin: A novel marker for oral cancer risk in
patients with oral premalignancy. J
Clin Oncol. 2008;26:354-60.
https://doi.org/10.1200/JCO.2007.13.4072
PMid:18202409
|
|
|
|
|
17. Yuan P,
Temam S, Naggar AE, Zhou X, Liu DD, Lee JJ, et al. Overexpression of podoplanin
in oral cancer and its association with poor clinical
outcome. Cancer
2006;107:563-9.
https://doi.org/10.1002/cncr.22061
PMid:16804930
|
|
|
|
|
18. Funayama A,
Cheng J, Maruyama S, Yamazaki M, Kobayashi T,Syafriadi
M, et al. Enhanced expression of podoplanin in oral
carcinomas in situ and squamous cell carcinomas. Pathobiol.
2011;78:171-80.
https://doi.org/10.1159/000324926
PMid:21613804
|
|
|
|
|
19. Vormittag L, Thurnher D,
Geleff S. Co-expression of bmi-1 and podoplanin
predicts overall survival in patients with squamous
cell carcinoma of the head and neck treated with
radio(chemo)therapy. Int J Radiat Oncol Biol Phys.
2009;73:913-18.
https://doi.org/10.1016/j.ijrobp.2008.10.040
PMid:19215825
|
|
|
|
|
20. Kreppel M, Kreppel B,
Drebber U, Wedemayer I, Rothamel D, Zoller JE, et al.
Podoplanin expression in oral leukoplakia: prognostic
value and clinicopathological implications. Oral
Dis. 2012;18:692-9.
https://doi.org/10.1111/j.1601-0825.2012.01927.x
PMid:22471854
|
|
|
|
|
21. de Vincent
JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-
Fernandez P, Allonca E, Garcia Pedrero JM. Podoplanin expression in oral
leukoplakia: tumorigenic role. Oral Oncol.
2013;49:598-603.
https://doi.org/10.1016/j.oraloncology.2013.02.008
PMid:23473850
|
|
|
|
|
22. Akinyamoju AO, Adeyemi BF,
Kolude B, Adisa AO. Histological grading of oral
squamous cell carcinoma patients in Ibadan using
Bryne's and Broders' grading systems- a comparative
study. Afr J Med Med Sci.
2013;42:333-7
PMid:24839737
|
|
|
|
|
23. Pindborg J, Sirsat S. Oral
submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral
Radiol. 1966;22:764.
https://doi.org/10.1016/0030-4220(66)90367-7
PMid:5224185
|
|
|
|
|
24. Patil A, Patil K,
Tupsakhare S, Gabhane M, Sonune S, Kandalgaonkar S.
Evaluation of podoplanin in oral leukoplakia and oral
squamous cell carcinoma. Scientifica
(Cairo). 2015;2015:135298.
https://doi.org/10.1155/2015/135298
PMid:26558136 PMCid:PMC4618324
|
|
|
|
|
25. Speight PM, Farthing PM,
Bouquot JE. The pathology of oral cancer and precancer.
Curr
Diag Path.1997;3:165-7.
https://doi.org/10.1016/S0968-6053(05)80014-6
|
|
|
|
|
26. Prasad B, Kashyap B, Babu
G, Kumar G, Manyam R. Expression of podoplanin in
different grades of oral squamous cell carcinoma. Ann
Med Health Sci Res. 2015;5:299-304.
https://doi.org/10.4103/2141-9248.160181
PMid:26229720 PMCid:PMC4512124
|
|
|
|
|
27. Kreppel M, Scheer M,
Drebber U, Ritter L, Zoller JE. Impact of podoplanin
expression in oral squamous cell carcinoma: clinical
and histopathologic correlations. Virchows
arch. 2010;456:473-82.
https://doi.org/10.1007/s00428-010-0915-7
PMid:20393745
|
|
|
|
|
28. Schacht V, Dadras SS, Johnson
LA, Jackson DG, Hong YK, Detmar M: Up-regulation of the
lymphatic marker podoplanin, a mucin-type transmembrane
glycoprotein, in human squamous cell carcinomas and
germ cell tumors. Am J Pathol.
2005;166:913-21.
https://doi.org/10.1016/S0002-9440(10)62311-5
|
|
|
|
|
29. Margaritescu
C, Raica M, Pirici D, Simionescu C, Mogoanta L, Stinga AC,
et al. Podoplanin expression in tumor-free resection
margins of oral squamous cell carcinomas: an
immunohistochemical and fractal analysis study. Histol
Histopathol. 2010; 25:701-11.
PMid:20376776
|
|
|
|
|
30. Miyasaki Y,
Okamoto E, Gonzalez- Alva P, Hayashi J, Ishige T,
Kikuchi, et al. The significance of podoplanin
expression in human inflamed gingiva. J Oral Sci. 2009;51:283-7.
https://doi.org/10.2334/josnusd.51.283
PMid:19550098
|
|